Home » Celsion Announces Resubmission With Philips Healthcare of Combined IND/IDE Application for a Phase II Study of ThermoDox, MR-Guided HIFU in Bone Cancer
Celsion Announces Resubmission With Philips Healthcare of Combined IND/IDE Application for a Phase II Study of ThermoDox, MR-Guided HIFU in Bone Cancer
Celsion announced a joint resubmission with Philips Healthcare of an IND/IDE application with the FDA for a Phase II clinical study of Celsion’s ThermoDox combined with Philips’ Sonalleve MR-HIFU technology for the treatment of prostate cancer metastases to the bone.
SYS-CON Media
SYS-CON Media
Upcoming Events
-
07May
-
14May
-
30May